Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CASI Pharmaceuticals ( (CASI) ) has shared an announcement.
On August 4, 2025, CASI Pharmaceuticals announced the FDA clearance of an IND application for CID-103, an anti-CD38 monoclonal antibody, aimed at treating renal allograft antibody-mediated rejection (AMR) in adults. This milestone allows CASI to initiate a Phase 1 clinical trial to evaluate the safety and efficacy of CID-103, which could address the significant challenge of AMR in kidney transplantation, potentially impacting the company’s positioning in the biopharmaceutical industry.
The most recent analyst rating on (CASI) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on CASI Pharmaceuticals stock, see the CASI Stock Forecast page.
Spark’s Take on CASI Stock
According to Spark, TipRanks’ AI Analyst, CASI is a Neutral.
CASI Pharmaceuticals’ overall stock score reflects significant financial challenges, including declining revenue, high leverage, and poor cash flow. The technical analysis suggests a bearish trend, while valuation metrics highlight ongoing profitability issues. These factors cumulatively result in a low overall score.
To see Spark’s full report on CASI stock, click here.
More about CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the U.S., and globally. The company specializes in hematology oncology therapeutics and treatments for organ transplant rejection and autoimmune diseases, leveraging its regulatory and commercial expertise in the Greater China market.
Average Trading Volume: 127,584
Technical Sentiment Signal: Sell
Current Market Cap: $19.99M
Find detailed analytics on CASI stock on TipRanks’ Stock Analysis page.